title: Axitinib affects cell viability and migration of a primary foetal lung adenocarcinoma culture.
abstract: Fetal lung adenocarcinoma (FLAC) is a rare variant of lung adenocarcinoma. Studies regarding FLAC have been based only on histopathological observations, thus representative in vitro models of FLAC cultures are unavailable. We have established and characterized a human primary FLAC cell culture, exploring its biology, chemosensitivity, and migration. FLAC cells and specimen showed significant upregulation of VEGF165 and HIF-1α mRNA levels. This observation was confirmed by in vitro chemosensitivity and migration assay, showing that only Axitinib was comparable to Cisplatin treatment. We provide a suitable in vitro model to further investigate the nature of this rare type of cancer.
authors.affiliation: 1Department of Thoracic Surgery, "G. Mazzini" Hospital, Faculty of Medicine and Surgery, University of L'Aquila , Teramo , Italy.
authors.forename: Cecilia
authors.initials: C
authors.lastname: Menna
authors.forename: Elena
authors.initials: E
authors.lastname: De Falco
authors.forename: Luca
authors.initials: L
authors.lastname: Pacini
authors.forename: Gaia
authors.initials: G
authors.lastname: Scafetta
authors.forename: Paola
authors.initials: P
authors.lastname: Ruggieri
authors.forename: Rosa
authors.initials: R
authors.lastname: Puca
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Petrozza
authors.forename: Anna Maria
authors.initials: AM
authors.lastname: Ciccone
authors.forename: Erino Angelo
authors.initials: EA
authors.lastname: Rendina
authors.forename: Antonella
authors.initials: A
authors.lastname: Calogero
authors.forename: Mohsen
authors.initials: M
authors.lastname: Ibrahim
mesh_terms: D000230:Adenocarcinoma / Q000000981:diagnostic imaging / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D000077192:Adenocarcinoma of Lung; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000494:pharmacology*; D000077784:Axitinib; D002465:Cell Movement / Q000187:drug effects*; D002470:Cell Survival / Q000187:drug effects; D002945:Cisplatin / Q000494:pharmacology; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000235:genetics / Q000378:metabolism; D007093:Imidazoles / Q000494:pharmacology*; D007191:Indazoles / Q000494:pharmacology*; D008175:Lung Neoplasms / Q000000981:diagnostic imaging / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D012333:RNA, Messenger / Q000378:metabolism; D011859:Radiography; D014407:Tumor Cells, Cultured; D015854:Up-Regulation; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; C497442:HIF1A protein, human; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D007093:Imidazoles; D007191:Indazoles; D047428:Protein Kinase Inhibitors; D012333:RNA, Messenger; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000077784:Axitinib; D002945:Cisplatin